Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
← catalyst calendarNCT07101094 · readout in 896 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
300estimated
Sites
20
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-22 | actual | When the study began enrolling |
| Primary completion | 2029-01-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-05-14 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Schizophrenia
Intervention
- Drug: xanomeline and trospium chloride (X/T) therapy
Primary outcomes
what the primary-completion date above is the date OFParticipant medication preference as assessed by the Preference of Medication (POM) questionnaire
measured Month 1, Month 3, Month 6
Participant treatment satisfaction as assessed by the Medication Satisfaction Questionnaire (MSQ)
measured Baseline, Month 1, Month 3, Month 6
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed